Biotricity, Inc. (BTCY)
OTCMKTS · Delayed Price · Currency is USD
0.2800
+0.0050 (1.82%)
Dec 30, 2025, 2:59 PM EST
Biotricity Revenue
Biotricity had revenue of $3.89M in the quarter ending September 30, 2025, with 18.95% growth. This brings the company's revenue in the last twelve months to $15.08M, up 19.51% year-over-year. In the fiscal year ending March 31, 2025, Biotricity had annual revenue of $13.79M with 14.32% growth.
Revenue (ttm)
15.08M
Revenue Growth
+19.51%
P/S Ratio
0.54
Revenue / Employee
327.86K
Employees
46
Market Cap
8.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13.79M | 1.73M | 14.32% |
| Mar 31, 2024 | 12.06M | 2.42M | 25.15% |
| Mar 31, 2023 | 9.64M | 1.99M | 26.00% |
| Mar 31, 2022 | 7.65M | 4.27M | 126.02% |
| Mar 31, 2021 | 3.38M | 1.97M | 138.75% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Biotricity News
- 6 days ago - The Zacks Analyst Blog Highlights Hims & Hers Health, Biotricity and Privia Health - Nasdaq
- 6 weeks ago - Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq
- 6 weeks ago - Biotricity GAAP EPS of -$0.03, revenue of $3.9M in-line - Seeking Alpha
- 6 weeks ago - Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026 - GlobeNewsWire
- 7 weeks ago - Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th - GlobeNewsWire
- 4 months ago - Biotricity (BTCY) Expands Market Reach Through New Partnership - GuruFocus
- 4 months ago - Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users - PRNewsWire